Back to search
FDAFDA · Food and drugs·Recall number D-1314-2020

Olanzapine Tablets, USP 2.5 mg, 30-count bottle, Rx only, Manufactured for: Prasco Laboratories Mason, OH 45040 USA, Manufactured by: Aurolife Pharma LLC Dayton, NJ 08810, NDC 66993-680-30

Published June 24, 2020 · Recall initiated: May 26, 2020

Summary

FDA records drug Class III recall D-1314-2020, published June 24, 2020 and initiated May 26, 2020. Recalling firm: Aurobindo Pharma USA Inc.; Status: Terminated; Reported quantity: 13322 bottles; Lot: Lot #: 561180046A1, Exp 8/2020. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/ Degradation Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Aurobindo Pharma USA Inc.
Distributor
U.S.A. Nationwide
Lot
Lot #: 561180046A1, Exp 8/2020
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Olanzapine Tablets, USP 2.5 mg, 30-count bottle, Rx only, Manufactured for: Prasco Laboratories Mason, OH 45040 USA, Manufactured by: Aurolife Pharma LLC Dayton, NJ 08810, NDC 66993-680-30 recalled?

Yes. FDA published recall D-1314-2020 on June 24, 2020. Reported hazard: Failed Impurities/ Degradation Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter